KW
Kwangdong Healthbio Co., Ltd.
086220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7086220001
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청원군 오창읍 양청송대길 39(송대리), 오창읍
- Website:
- http://www.kd-healthbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2025-05-21 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.1 KB | ||
| 2025-03-25 00:00 |
AGM Information
정기주주총회결과
|
Korean | 15.2 KB | ||
| 2025-03-17 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 9.6 KB | ||
| 2025-03-17 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 436.1 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 114.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 26.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 25.1 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 8.4 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 28.6 KB | ||
| 2024-12-11 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.4 KB | ||
| 2024-10-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-10-14 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2024-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.3 KB | ||
| 2024-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.6 KB |
Automate Your Workflow. Get a real-time feed of all Kwangdong Healthbio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Kwangdong Healthbio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kwangdong Healthbio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
South Korea
067370
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
United States of America
SBFM
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
United States of America
SUPN
Provides medical device coatings, vascular products, and components for diagnostic tests.
United States of America
SRDX
United States of America
SRDX
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
United States of America
STRO
/other/Swedencare_AB_publ-logo.png){kind=logo}
Develops and markets premium health supplements and pharmaceuticals for cats, dogs, and horses.
Sweden
SECARE
Sweden
SECARE
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
Sweden
SOBI
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
Japan
4582
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT
Sweden
SYNACT
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom
SNG
United Kingdom
SNG